https://orcid.org/0000-0003-4962-6808
Figures
Abstract
Objectives
A systematic review was conducted in high-income country settings to analyse: (i) spina bifida neonatal and IMRs over time, and (ii) clinical and socio-demographic factors associated with mortality in the first year after birth in infants affected by spina bifida.
Data sources
PubMed, Embase, Ovid, Web of Science, CINAHL, Scopus and the Cochrane Library were searched from 1st January, 1990 to 31st August, 2020 to review evidence.
Study selection
Population-based studies that provided data for spina bifida infant mortality and case fatality according to clinical and socio-demographical characteristics were included. Studies were excluded if they were conducted solely in tertiary centres. Spina bifida occulta or syndromal spina bifida were excluded where possible.
Data extraction and synthesis
Independent reviewers extracted data and assessed their quality using MOOSE guideline. Pooled mortality estimates were calculated using random-effects (+/- fixed effects) models meta-analyses. Heterogeneity between studies was assessed using the Cochrane Q test and I2 statistics. Meta-regression was performed to examine the impact of year of birth cohort on spina bifida infant mortality.
Results
Twenty studies met the full inclusion criteria with a total study population of over 30 million liveborn infants and approximately 12,000 spina bifida-affected infants. Significant declines in spina bifida associated infant and neonatal mortality rates (e.g. 4.76% decrease in IMR per 100, 000 live births per year) and case fatality (e.g. 2.70% decrease in infant case fatality per year) were consistently observed over time. Preterm birth (RR 4.45; 2.30–8.60) and low birthweight (RR 4.77; 2.67–8.55) are the strongest risk factors associated with increased spina bifida infant case fatality.
Significance
Significant declines in spina bifida associated infant/neonatal mortality and case fatality were consistently observed, advances in treatment and mandatory folic acid food fortification both likely play an important role. Particular attention is warranted from clinicians caring for preterm and low birthweight babies affected by spina bifida.
Citation: Ho P, Quigley MA, Tatwavedi D, Britto C, Kurinczuk JJ (2021) Neonatal and infant mortality associated with spina bifida: A systematic review and meta-analysis. PLoS ONE 16(5): e0250098. https://doi.org/10.1371/journal.pone.0250098
Editor: Harald Ehrhardt, Center of Pediatrics, GERMANY
Received: November 19, 2020; Accepted: March 30, 2021; Published: May 12, 2021
Copyright: © 2021 Ho et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the manuscript and its Supporting Information files.
Funding: This paper reports on an independent study which is part-funded by the NIHR Policy Research Programme in the Department of Health & Social Care. The views expressed are not necessarily those of the Department. Peter Ho is funded by a Clarendon – Green Templeton College – Nuffield Department of Population Health Scholarship, University of Oxford. The funders did not play any role in the study design, data collection and analyses, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Neural tube defects (NTDs) constitute the largest group of congenital anomalies of the central nervous system [1]; the aetiology of spina bifida is multifactorial [2,3]. Mortality among infants with spina bifida has been previously investigated in several studies, mainly restricted to selected geographical regions especially in high-income countries where data are more available [4].
Infant mortality associated with spina bifida has been changing over time depending on various factors including folic acid supplementation and food fortification programme [5], prenatal screening [6], treatment and termination of pregnancy [7], and the health care system to tract and link all cases with death registers [4]. We conducted a systematic review and meta-analysis of population-based studies focusing on liveborn infants with spina bifida in high-income countries.
The aims of this study were to assess: (1) spina bifida- specific neonatal and infant mortality rates over time; and (2) the socio-demographic and clinical factors associated with mortality in the first year for infants affected by spina bifida.
Methods
The methods for the overall systematic review have been registered as a review protocol in the International Prospective Register of Systematic Reviews (PROSPERO) [8], registration number CRD42018081353.
Search strategy
Comprehensive literature searches of PubMed, Embase, Ovid, Web of Science, CINAHL, Scopus and the Cochrane Library was performed from 1st January, 1990 to 31st August, 2020. MeSH terms and keywords which included neural tube defect or congenital brain malformation or abnormalities or spina bifida and infant or neonatal or perinatal and mortality or death or survival etc. were entered systematically into the databases. The detailed search terms are shown in S1 Table. There were no language restrictions applied. Manual searches of reference lists were performed on all the included publications. Attempts were also made to contact the study authors for any relevant unpublished data where appropriate.
Titles and abstracts of all identified studies were screened by PH according to the inclusion criteria. For articles which satisfied the first screen, full articles were then screened independently by two reviewers (PH and DT/ CB) for their eligibility according to the full inclusion and exclusion criteria. Any discrepancies were reviewed by the author review team (PH, MQ and JK) to reach a final decision.
Eligibility criteria
Population-based studies were included if they (1) ascertained all individuals born with spina bifida in a predefined population; (2) provided data for spina bifida infant mortality (defined as the number of spina bifida associated deaths under one year of age occurring among all livebirths in a given population) or case fatality (defined as the proportion of spina bifida associated deaths among all spina bifida cases under one year of age in a given population), or case fatality estimates according to clinical or socio-demographical characteristics; and (3) were conducted in high-income countries as defined by the World Bank [9].
Studies were excluded if: (1) they were conducted solely in tertiary or referral centres; and (2) spina bifida-affected individuals were not followed up from birth. Spina bifida occulta (i.e. a mild form of spina bifida with no clinical consequence) or spina bifida related to a syndrome were excluded where possible.
For multiple papers which overlapped in time, study region and objectives [3,10–22], only the study (or a combination of studies) with the best quality, largest population size, and covering the longest and most recent periods were included.
Data extraction
PH conducted the literature searches with the assistance of a specialist information librarian, screening of abstracts and review of 368 eligible full articles. DT and CB each reviewed 50% of the eligible full articles, validated decisions about the final included articles and extracted data.
The following data were extracted: study population, study design, sample size, country of study, and descriptive/ mortality data about maternal age, maternal ethnicity, smoking, maternal education, previous live births, prenatal care, induction of labour, mode of delivery, infant sex, gestational age, birthweight, year of birth, plurality, lesion level, the presence of multiple defects, hydrocephalus and major cardiac defects and period of folic acid fortification.
Spina bifida mortality rates, case fatality and the corresponding 95% CI were extracted at the age of one month and one year. If the 95% CI of the mortality rates were not reported, they were estimated using ‘binomial exact’, assuming no cases were censored. In studies where 95% CI of relative risks (RR) of factors for mortality were not reported, they were estimated using log RR ± 1.96 × Standard Error, where standard error was derived from the counts and proportions.
Statistical analysis.
As all the pooled estimates for mortality risk factors rate ratios came from two studies [10–12,23], both random-effects and fixed effects models were used to calculate and compare the pooled estimates. These studies were conducted during pre- mandatory folic acid food fortification period, which justified the decision for the effects pooling. Heterogeneity between studies was assessed using the Cochrane Q test and I2 statistics, p < 0.10 was considered as statistically significant with I2 > 50% indicating a substantial level of heterogeneity. Random-effects meta-regression was used to assess the effect of year of birth. Results of meta-regressions are presented in bubble plots, where the weights used to determine the bubble size are the inverses of the effect-size variances and hence the size of the bubble is proportional to the precision of each study. The slopes of the meta-regression lines were calculated, with p < 0.05 considered as statistically significant.
All data analyses were performed using Stata version 13 (StataCorp). The reporting of results was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram and Meta-analysis of Observation Studies in Epidemiology (MOOSE) checklist [24,25].
Quality appraisal.
Risk of bias (RoB) assessment was conducted using a refined quality tool based on Quality in Prognostic Studies (QUIP) [26] for the following domains: study participation, measurement of outcome(s), study attrition, measurement of exposure or prognostic factor(s) and statistical analysis and reporting. Each domain was rated either as ‘high’, ‘moderate’ or ‘low’ RoB by two independent reviewers (PH and DT/CB). The overall RoB for each included study was assessed using the method described by Hayden et al. [27] in line with the Cochrane Risk of Bias tool [28].
Results
The flow of literature in this review is summarised in the PRISMA diagram (Fig 1). Of 5,023 articles identified, 20 met the inclusion criteria.
Study characteristics
All 20 included studies were population-based cohort studies conducted in high-income countries, with six studies in the U.S. (mandatory folic acid food fortification introduced in 1998) [3,10–12,29,30], four in Canada (mandatory folic acid food fortification introduced in 1998) [31–34], four in Australia (mandatory folic acid food fortification introduced in 2009) [23,35–37], two in Republic of Ireland [38,39], one in the UK (Scotland) [40] and one in Sweden [41], one in Denmark [42], and one from the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) selected member registries of France, Germany, Italy, Netherlands, Spain, Sweden and UK Wales [43] (Table 1). These studies included a total study population of over 30 million liveborn infants (median study sample size: 1,178,452, range: 251,699–14 million) in which approximately 12,000 (median: 231 and range: 27–3,903) were affected by spina bifida. All infants included were born at ≥20 weeks gestational age with a birthweight ≥500g.
Multiple defects.
One study [41] reported that 37% of spina bifida cases were associated with hydrocephalus which was analysed separately. Eleven studies [29,10–12,24,31,38–40,43] reported that between 2.7% and 43.6% of spina bifida cases were associated with multiple anomalies or a syndrome. One study [44] reported that 7% of spina bifida cases were associated with major cardiac defects.
Cases of syndromal spina bifida were excluded from the analysis in three studies [10,39,40]; Whether syndromal spina bifida were included in other studies [3,10–12,23,29–36,38,41] was uncertain as we were unable to verify this with the authors.
Mortality estimates
Decreasing trends in neonatal and infant mortality rates, and case fatality from spina bifida were observed in different high-income countries over time (Tables 2 and 3). For example, the spina bifida neonatal mortality rate (NMR) was 17.0 (95% CI: 14.2–19.8) per 100, 000 live births in 1983–1995 in Australia during pre- mandatory folic acid food fortification [35], compared to the spina bifida NNR at 1.6 (95% CI: 1.4–1.8) per 100, 000 live births in 1999–2007 [30] in the U.S. during post- mandatory folic acid fortification. In Canada and the U.S., the spina bifida infant IMR reduced from 23.0 (95% CI: 19.3–27.2) per 100, 000 live births in 1981–1983 [34] to 2.3 (95% CI: 2.0–2.5) per 100, 000 live births in 1990–2007 [30]. Similarly, in Australia, the spina bifida neonatal case fatality decreased from the highest reported 63% (95% CI: 55–72%) in 1966–1972 [23] to the lowest reported 16% (95% CI: 7–24%) in 1986–1990 [23]; and the spina bifida infant case fatality decreased from the highest at 68.3% in 1973–79 to the lowest at 19.6% in 2004–09 (pre-mandatory folic acid food fortification) [23,37]. In Canada, the infant case fatality decreased from 31% (95% CI: 23–40%) in 1967–1974 [31] to 9% (95% CI: 5–13%) in 1975–1990 [31].
There was considerable heterogeneity between studies for spina bifida NMR (I2 = 99.6%, p <0.001), IMR (I2 = 99.5%, p <0.001), neonatal case fatality (I2 = 98.7%, p < 0.001), and infant case fatality (I2 = 99.1%, p <0.001) (Tables 2 and 3). The fitted meta-regression shows a decrease over time in NMR [30,35,40] and IMR [3,30,33,34] due to spina bifida (slope = 7.14% and 4.76% decrease in death rate per 100, 000 live births per year respectively, p <0.001) (Figs 2 and 3), and in neonatal [10,23,30,35,37–40,42,43] and infant [29,10,23,30,31,37,38,42,43] case fatality (slope = 2.44% and 2.70% decrease per year respectively, p <0.001) (Figs 4 and 5). It is also important to note that the case fatality estimates from 1973–1979 were extremely high, which was due to strict selection criteria for surgical treatment of infants with spina bifida during the period [23]. In our sensitivity analysis, after the case fatality estimates from 1973–1979 reported by Kalucy et al. [23] were excluded, the decrease in neonatal and infant case fatality remained the same (slope = 2.44% and 2.70% decrease per year respectively, p <0.001).
Risk factors for infant case fatality
Meta-analyses showed that preterm birth (i.e. <37 weeks of gestation) [10,11], low birthweight (i.e. <2500g) [10,12], cervico-thoracic lesion level [10,12], presence of hydrocephalus [10,23], multiple defects [10,11], and maternal black ethnicity [10,12] were independently and significantly associated with an increased risk of death among infants with spina bifida after adjustment for other factors in the respective studies, with preterm birth (RR 4.45, 95% CI: 2.30–8.60) and low birthweight (RR 4.77; 95% CI: 2.67–8.55) being the strongest risk factors associated with increased spina bifida infant case fatality (Table 4 and Figs 6–11).
Spina bifida infant case fatality risk factors.
Spina bifida infant case fatality risk factors.
Spina bifida infant case fatality risk factors.
Spina bifida infant case fatality risk factors.
Spina bifida infant case fatality risk factors.
Spina bifida infant case fatality risk factors.
Other significant risk factors for spina bifida case fatality reported in single studies included plurality (multiple vs. singleton: RR 2.57; 2.07–3.07) [12], induction of labour (yes vs. no: RR 2.49; 2.21–2.76) [11], maternal marital status (not married vs. married: RR 1.31; 1.04–1.57) [11], prenatal care (inadequate vs. adequate: RR 1.74; 1.36–2.12) [11]. Importantly, mandatory folic acid food fortification was significantly associated with a reduced hazard ratio of spina bifida infant case fatality (HR 0.68; 95% CI: 0.50–0.91) [11]. Infant sex, maternal age, maternal education, maternal smoking, previous live births and method of delivery were not significantly associated with case fatality for infants born with spina bifida [11,12]. (S2 Table).
Quality appraisal
Results of the quality appraisal of evidence are summarised in Fig 12. The majority of the included studies satisfied the study population domain as they were national or register-based. The exposure/ prognostic factors measurement domain was satisfied in about half of the included studies, this was mainly due to the differences in treatment and preventative interventions available over time and between countries of the studies, as well as variations between studies in reporting syndromal and multiple defects which is a major prognostic factor. The statistical analysis and reporting domain was satisfied only in one-fifth of the included studies due to a combination of concurrent cases [11,38], missing data, unreported 95% CI [12,29], and the potential for incomplete ascertainment of deaths particularly in early surveillance programmes [11,30,35,41]. In addition, some studies did not perform mortality analysis but only reported the number of infants alive or dead, in which cases censoring was not accounted for. Infant mortality and case fatality estimates may have been underestimated in these studies.
Discussion
This systematic review included 20 population-based cohort studies with a total study population of over 30 million liveborn infants, in which approximately 12,000 liveborn infants were affected by spina bifida; outcomes were reported based on generally high-quality evidence from studies mainly with a low to moderate risk of bias. The review spanned 49 years with births from 1966 to 2015. Variation in study period is perhaps the main source of heterogeneity for the mortality estimates. This is largely indicative of different clinical and interventional exposures to which the patient populations were subject to over time.
Spina bifida infant mortality encompasses both to the chance of being born with spina bifida as well as surviving with the condition during infancy (i.e. case fatality), both of which have significantly decreased over time. There are several possible mechanisms including:
First, primary prevention: Five large population-based US cohort studies in this review have consistently shown a significant decline over time in spina bifida infant mortality post mandatory folic acid fortification of U.S. grain supply introduced in September 1998 [3,13,30,33–45]. This finding is consistent with long term surveillance data from the U.S., Canada, Chile and Costa Rica where folic acid food fortification had been successfully implemented, showing that the NTD birth prevalence can be reduced over time to as low as 5–6 per 100,000 pregnancies [9,46]. Indeed, the original large (n = 1,817 women at high risk of having a pregnancy with a NTD) international randomised double-blind prevention trial conducted by the MRC Vitamin Study Research Group showed a 72% protective effect against the occurrence of an NTD (i.e. spina bifida, encephalocele and anencephaly) pregnancy for women taking 4 mg folic acid supplementation daily prior to conception [5]. Similarly, in a large population-based cohort study, Berry et al. (1999) have shown that periconceptional intake of folic acid reduce the risk of NTDs in areas with variable prevalence rates in China [47]. These findings established the specific role of folic acid supplementation in the prevention of NTDs.
Second, the studies by Kalucy et al. (1994) [23], Riley et al. (1998) [35], Wen et al. (1999) [32] and Davidoff et al. (2002) [3] have shown that spina bifida infant mortality and case fatality declined over time prior to national implementation of folic acid food fortification in Australia and the U.S‥ This finding suggests that improved technology in and access to prenatal screening and diagnosis over time in high-income countries have led to significant declines in both late fetal death and birth of spina bifida affected infants as a result of early prenatal diagnosis and termination of pregnancy [23,48]. According to EUROCAT data, over 50–75% of cases of spina bifida are terminated in Europe [49].
Possible explanations for the decline in spina bifida infant case fatality over time include:
First, folic acid food fortification: This review has shown a significant decline over time in spina bifida infant case fatality post mandatory folic acid fortification of the U.S. grain supply [3,13,30,33,34]. Infants born with a spina bifida during the period of mandatory fortification were almost one-third less likely to die in infancy compared to infants born with a spina bifida during pre-fortification period [11]. Studies suggest that folic acid food fortification, may reduce the risk of severe types of spina bifida by moving the lesion caudally along the developing spine [11,50–52], as upper-level spina bifida is associated with more severe anomalous brain development and more system wide complications compared with lower-level spina bifida [42,53].
Second, advances in medical and surgical interventions: Studies have suggested that improved ventilator support in neonatal intensive care and the use of antibiotics to treat CNS infections have provided better treatment of spina bifida and associated co-morbidities such as prematurity and low birthweight which have been shown as the strongest predictors for infant deaths in this review [54]. In addition, advances in surgical treatment for spina bifida and associated hydrocephalus and cardiac defects may also have contributed to the reductions in case fatality [31,50,55–60].
Regarding other risk factors, mortality among Black and Hispanic infants with spina bifida has declined with time but remains consistently higher when compared to White infants [12]. Possible explanations include barriers to access to health care particularly among women of lower socioeconomic classes [12,61,62]. Hispanic populations also have a high incidence of C677T methylenetetrahydrofolate reductase (MTHFR) homozygous genotype mutations [62,63] which have been shown to be associated with upper level spina bifida defects [64]. Fetuses with an anomaly often have other developmental effects during gestation which may also lead to preterm birth [65,66]. Therefore, preterm birth and congenital anomalies are likely to have a multiplicative effect on infant mortality. Multiple anomalies are an indicator of disease complications and severity, and hence tend to be associated with poorer prognosis when major systems are involved, compared to isolated anomalies [43,67].
The main strengths of this review include its comprehensive search strategy with no language restriction, robust inclusion criteria and complete coverage of liveborn spina bifida population-based studies. Unpublished relevant data were obtained from study authors and included in the analysis where possible. A further strength is the generally high quality of the included studies with the majority of studies rated as low to moderate risk of bias according to the refined QUIP and Cochrane RoB tool [26,28].
There are several limitations. First, mortality in infants with spina bifida depends on various factors including health care systems, treatment, termination of pregnancy and ability to track and link all cases with death registers. Without the availability of these data, it is not possible to determine the true underlying cause of the reduction in infant case fatality and mortality rates. In addition, we could not verify whether multiple defects and syndromal spina bifida were included or excluded in the majority of the included studies. Consequently, these potentially caused high variability and heterogeneity in the estimates. Second, study data about risk factors for spina bifida case fatality were limited; in particular, data about women intake of folic acid supplement was not available in most of the included studies, which is an important factor to account for. Finally, cases of multiple defects and syndrome associated with spina bifida cannot be completely excluded from the analysis as they cannot be reliably identified in most of the included studies.
Conclusions
This study has reviewed the evidence about spina bifida infant mortality in high-income countries. This study has shown that a decline in spina bifida associated infant/neonatal mortality and case fatality were consistently observed, in which advances in medical and surgical treatment, and mandatory folic acid food fortification likely to play an important role. Preterm birth and low birthweight are strongest risk factors associated with increased case fatality of infants with spina bifida, which warrant particular attention from clinicians caring for these vulnerable babies.
Supporting information
S1 Table. Detailed search terms using PubMed online database.
https://doi.org/10.1371/journal.pone.0250098.s002
(DOCX)
S2 Table. Other risk factors for spina bifida infant case fatality from single studies (relative risk estimates).
https://doi.org/10.1371/journal.pone.0250098.s003
(DOCX)
Acknowledgments
We thank Ms. Nia Wyn Roberts, Outreach Librarian Bodleian Health Care Libraries, Knowledge Centre, Oxford University, UK for her contribution on the literature search strategies; Dr. Sarah Stock, Senior Clinical Lecturer, Honorary Consultant and Subspecialist in Maternal and Fetal Medicine, MRC Centre for Reproductive Health, University of Edinburgh Queen’s Medical Research Institute, UK and Professor Falah Maroun, Clinical Professor of Neurosurgery, Faculty of Medicine, Memorial University, Canada for providing further data for this review.
References
- 1.
Kurinczuk J.J., Hollowell J., Boyd P.A., Oakley L., Brocklehurst P. and Gray R., 2010. Inequalities in infant mortality project briefing paper 4. The contribution of congenital anomalies to infant mortality. Oxford: National Perinatal Epidemiology Unit, 2010.
- 2. Blencowe H, Cousens S, Modell B, Lawn J. Folic acid to reduce neonatal mortality from neural tube disorders. International journal of epidemiology. 2010 Apr 1;39(suppl_1):i110–21. pmid:20348114
- 3. Davidoff MJ, Petrini J, Damus K, Russell RB, Mattison D. Neural tube defect‐specific infant mortality in the United States. Teratology. 2002;66(S1):S17–22. pmid:12239739
- 4. Rosano A, Botto LD, Botting B, Mastroiacovo P. Infant mortality and congenital anomalies from 1950 to 1994: an international perspective. Journal of Epidemiology & Community Health. 2000 Sep 1;54(9):660–6.
- 5. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. The lancet. 1991 Jul 20;338(8760):131–7. pmid:1677062
- 6.
Royal College of Obstetricians and Gynaecologists. Termination of Pregnancy for Fetal Abnormality in England, Scotland and Wales. Report of a working party. 2010.
- 7. Thompson DN. Postnatal management and outcome for neural tube defects including spina bifida and encephalocoeles. Prenatal Diagnosis: Published in Affiliation With the International Society for Prenatal Diagnosis. 2009 Apr;29(4):412–9. pmid:19194999
- 8.
PROSPERO International prospective register of systematic review, National Institute for Health Research, NHS [online]. [Assessed on 18.6.2019]. Available from https://www.crd.york.ac.uk/PROSPERO.
- 9.
The World Bank Data: High income [online]. [Assessed on 18.1.2019]. Available from https://data.worldbank.org/income-level/high-income.
- 10. Wong LY, Paulozzi LJ. Survival of infants with spina bifida: a population study, 1979–94. Paediatric and perinatal epidemiology. 2001 Oct;15(4):374–8. pmid:11703686
- 11. Bol KA, Collins JS, Kirby RS. Survival of infants with neural tube defects in the presence of folic acid fortification. Pediatrics. 2006 Mar 1;117(3):803–13. pmid:16510661
- 12. Shin M, Kucik JE, Siffel C, Lu C, Shaw GM, Canfield MA, Correa A. Improved survival among children with spina bifida in the United States. The Journal of pediatrics. 2012 Dec 1;161(6):1132–7. pmid:22727874
- 13. Wang Y, Hu J, Druschel CM, Kirby RS. Twenty‐Five–Year survival of children with birth defects in New York State: A population‐based study. Birth Defects Research Part A: Clinical and Molecular Teratology. 2011 Dec;91(12):995–1003. pmid:21960515
- 14. Benjamin R.H., Lopez A., Mitchell L.E., Tsao K., Johnson A., Langlois P.H., Swartz M.D. and Agopian A.J., 2019. Mortality by mode of delivery among infants with spina bifida in Texas. Birth defects research, 111(19), pp.1543–1550. pmid:31642615
- 15. Meyer R.E., Copeland G.E., Nembhard W., Kirby R.S., Wang Y., Liu G., Canfield M.A., Mai C.T., Gilboa S.M., Meyer R.E. and Anderka M., Racial/Ethnic Differences in Survival of United States Children with Birth Defects: A Population-Based Study.
- 16. Wang Y., Hu J. and Druschel C.M., 2010. A retrospective cohort study of mortality among children with birth defects in New York State, 1983–2006. Birth Defects Research Part A: Clinical and Molecular Teratology, 88(12), pp.1023–1031. pmid:20683907
- 17.
Sullivan, A.M., 2020. Spina Bifida Mortality by Clinical and Demographic Characteristics Using the New York State Birth Defects Registry, 2008–2016. State University of New York at Albany.
- 18. Correa A., Cragan J.D., Kucik J.E., Alverson C.J., Gilboa S.M., Balakrishnan R., Strickland M.J., Duke C.W., O’Leary L.A., Riehle-Colarusso T. and Siffel C., 2002. Metropolitan Atlanta Congenital Defects Program.
- 19. Agha MM, Williams JI, Marrett L, To T, Dodds L. Determinants of survival in children with congenital abnormalities: a long-term population-based cohort study. Birth Defects Res A Clin Mol Teratol. 2006;76(1):46–54. pmid:16397887.
- 20. Berger KH, Zhu BP, Copeland G. Mortality throughout early childhood for Michigan children born with congenital anomalies, 1992–1998. Birth Defects Res A Clin Mol Teratol. 2003;67(9):656–61. pmid:14703790.
- 21. Kancherla V., Ma C., Grant G., Lee H.C., Hintz S.R. and Carmichael S.L., 2020. Factors Associated with Early Neonatal and First-Year Mortality in Infants with Myelomeningocele in California from 2006 to 2011. American Journal of Perinatology. pmid:32473597
- 22.
Liu S., Joseph K.S. and Wen S.W., 2002, August. Trends in fetal and infant deaths caused by congenital anomalies. In Seminars in perinatology (Vol. 26, No. 4, pp. 268–276). WB Saunders. https://doi.org/10.1053/sper.2002.34776 pmid:12211617
- 23. Kalucy M, Bower C, Stanley F, Burton P. Survival of infants with neural tube defects in Western Australia 1966–1990. Paediatric and perinatal epidemiology. 1994 Jul;8(3):334–51. pmid:7997409
- 24. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews. 2015 Dec 1;4(1):1. pmid:25554246
- 25. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Jama. 2000 Apr 19;283(15):2008–12. pmid:10789670
- 26.
The QUIPS tool, Cochrane Methods Prognosis [online]. [Assessed on 15.1.2018]. Available from https://methods.cochrane.org/sites/methods.cochrane.org.prognosis/files/public/uploads/QUIPS%20tool.pdf.
- 27. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Annals of internal medicine. 2013 Feb 19;158(4):280–6. pmid:23420236
- 28. Higgins JP, Green S. Cochrane handbook for systematic reviews. The cochrane collaboration. 2008;5(0).
- 29. Waitzman NJ, Romano PS, Scheffler RM. Estimates of the economic costs of birth defects. Inquiry. 1994 Jul 1:188–205. pmid:8021024
- 30. Wang Y, Liu G, Canfield MA, Mai CT, Gilboa SM, Meyer RE, Anderka M, Copeland GE, Kucik JE, Nembhard WN, Kirby RS. Racial/ethnic differences in survival of United States children with birth defects: a population-based study. The Journal of pediatrics. 2015 Apr 1;166(4):819–26. pmid:25641238
- 31. Laishram H, Kennedy R, Maroun F, Price D. The impact of spina bifida on the medical services of Newfoundland and Labrador. Journal of pediatric surgery. 1993 Sep 1;28(9):1098–101. pmid:8308668
- 32. Wen SW, Liu S, Joseph KS, Trouton K, Allen A. Regional patterns of infant mortality caused by lethal congenital anomalies. Canadian Journal of Public Health. 1999 Sep 1;90(5):316–9. pmid:10570575
- 33. Liu S, Joseph KS, Wen SW, Kramer MS, Marcoux S, Ohlsson A, Sauve R. Secular trends in congenital anomaly‐related fetal and infant mortality in Canada, 1985–1996. American journal of medical genetics. 2001 Nov 15;104(1):7–13. pmid:11746021
- 34. Wen SW, Liu S, Joseph KS, Rouleau J, Allen A. Patterns of infant mortality caused by major congenital anomalies. Teratology. 2000 May;61(5):342–6. pmid:10777829
- 35. Riley MM, Halliday JL, Lumley JM. Congenital malformations in Victoria, Australia, 1983–95: an overview of infant characteristics. Journal of paediatrics and child health. 1998 Jun;34(3):233–40. pmid:9633969
- 36. Algert CS, Bowen JR, Hadfield RM, Olive EC, Morris JM, Roberts CL. Birth at hospitals with co‐located paediatric units for infants with correctable birth defects. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2008 Jun;48(3):273–9. pmid:18532958
- 37. Schneuer FJ, Bell JC, Shand AW, Walker K, Badawi N, Nassar N. Five‐year survival of infants with major congenital anomalies: a registry based study. Acta Paediatrica. 2019 Nov;108(11):2008–18. pmid:31046172
- 38. Sutton M, Daly LE, Kirke PN. Survival and disability in a cohort of neural tube defect births in Dublin, Ireland. Birth Defects Research Part A: Clinical and Molecular Teratology. 2008 Oct;82(10):701–9. pmid:18803309
- 39. McDonnell R, Delany V, O’Mahony MT, Mullaney C, Lee B, Turner MJ. Neural tube defects in the Republic of Ireland in 2009–11. Journal of Public Health. 2015 Mar 1;37(1):57–63. pmid:24643675
- 40. Theodorou D., et al. (2013). "A study of outcome in antenatally diagnosed cases of spina bifida in south east Scotland 1990–2009." Developmental Medicine and Child Neurology. 2013, 55: 31.
- 41. Persson EK, Hagberg G, Uvebrant P. Hydrocephalus prevalence and outcome in a population‐based cohort of children born in 1989–1998. Acta paediatrica. 2005 Jun;94(6):726–32. pmid:16188776
- 42. Borgstedt-Bakke JH, Fenger-Grøn M, Rasmussen MM. Correlation of mortality with lesion level in patients with myelomeningocele: a population-based study. Journal of Neurosurgery: Pediatrics. 2017 Feb 1;19(2):227–31. pmid:27911247
- 43. Bakker MK, Kancherla V, Canfield MA, Bermejo‐Sanchez E, Cragan JD, Dastgiri S, De Walle HE, Feldkamp ML, Groisman B, Gatt M, Hurtado‐Villa P. Analysis of Mortality among Neonates and Children with Spina Bifida: An International Registry‐Based Study, 2001‐2012. Paediatric and perinatal epidemiology. 2019 Nov;33(6):436–48. pmid:31637749
- 44.
Correa A, Lu C, Shin M, Siffel C, James K. What is the current survival of infants with spina bifida?. InBIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY 2008 May 1 (Vol. 82, No. 5, pp. 369–369). DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA: WILEY-LISS.
- 45. Kancherla V, Druschel CM, Oakley GP Jr. Population‐based study to determine mortality in spina bifida: New York State Congenital Malformations Registry, 1983 to 2006. Birth Defects Research Part A: Clinical and Molecular Teratology. 2014 Aug;100(8):563–75. pmid:24975407
- 46. Crider KS, Bailey LB, Berry RJ. Folic acid food fortification—its history, effect, concerns, and future directions. Nutrients. 2011 Mar;3(3):370–84. pmid:22254102
- 47. Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, Mulinare J, Zhao P, Wong LY, Gindler J, Hong SX. Prevention of neural-tube defects with folic acid in China. New England journal of medicine. 1999 Nov 11;341(20):1485–90. pmid:10559448
- 48. Boyle B, Addor MC, Arriola L, Barisic I, Bianchi F, Csáky-Szunyogh M, de Walle HE, Dias CM, Draper E, Gatt M, Garne E. Estimating Global Burden of Disease due to congenital anomaly: an analysis of European data. Archives of Disease in Childhood-Fetal and Neonatal Edition. 2018 Jan 1;103(1):F22–8. pmid:28667189
- 49.
European Surveillance of Congenital Anomalies (EUROCAT) Final Activity Report 2002–2003.
- 50. Mitchell LE, Adzick NS, Melchionne J, Pasquariello PS, Sutton LN, Whitehead AS. Spina bifida. The Lancet. 2004 Nov 20;364(9448):1885–95.
- 51. Oakeshott P, Hunt GM, Poulton A, Reid F. Expectation of life and unexpected death in open spina bifida: a 40‐year complete, non‐selective, longitudinal cohort study. Developmental Medicine & Child Neurology. 2010 Aug;52(8):749–53. pmid:20015251
- 52. Bowman RM, McLone DG, Grant JA, Tomita T, Ito JA. Spina bifida outcome: a 25-year prospective. Pediatric neurosurgery. 2001;34(3):114–20. pmid:11359098
- 53. Fletcher JM, Copeland K, Frederick JA, Blaser SE, Kramer LA, Northrup H, Hannay HJ, Brandt ME, Francis DJ, Villarreal G, Drake JM. Spinal lesion level in spina bifida: a source of neural and cognitive heterogeneity. Journal of Neurosurgery: Pediatrics. 2005 Apr 1;102(3):268–79. pmid:15881750
- 54. Charney EB, Melchionni JB, Antonucci DL. Ventriculitis in newborns with myelomeningocele. American Journal of Diseases of Children. 1991 Mar 1;145(3):287–90. pmid:2003476
- 55. Grivell RM, Andersen C, Dodd JM. Repair procedures for spina bifida for improving infant and maternal outcomes. Cochrane Database of Systematic Reviews. 2010(11).
- 56. Morris CD, Menashe VD. 25-year mortality after surgical repair of congenital heart defect in childhood: a population-based cohort study. Jama. 1991 Dec 25;266(24):3447–52. pmid:1744959
- 57. Date I, Yagyu Y, Asari S, Ohmoto T. Long-term outcome in surgically treated spina bifida cystica. Surgical neurology. 1993 Dec 1;40(6):471–5. pmid:8235969
- 58. Adzick NS, Thom EA, Spong CY, Brock JW III, Burrows PK, Johnson MP, Howell LJ, Farrell JA, Dabrowiak ME, Sutton LN, Gupta N. A randomized trial of prenatal versus postnatal repair of myelomeningocele. New England Journal of Medicine. 2011 Mar 17;364(11):993–1004. pmid:21306277
- 59. Ames MD, Schut L. Results of treatment of 171 consecutive myelomeningoceles—1963 to 1968. Pediatrics. 1972 Sep 1;50(3):466–70. pmid:5056422
- 60. Adams MM, Greenberg F, Khoury MJ, Marks JS, Oakley GP. Survival of infants with spina bifida—Atlanta, 1972–1979. American Journal of Diseases of Children. 1985 May 1;139(5):518–23. pmid:3885718
- 61. Canfield MA, Annegers JF, Brender JD, Cooper SP, Greenberg F. Hispanic origin and neural tube defects in Houston/Harris County, Texas: II. Risk factors. American journal of epidemiology. 1996 Jan 1;143(1):12–24. pmid:8533743
- 62. Botto LD, Yang Q. 5, 10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. American journal of epidemiology. 2000 May 1;151(9):862–77. pmid:10791559
- 63. Chowdary D, Streck D, Schwalb MN, Dermody JJ. High incidence of two methylenetetrahydrofolate reductase mutations (C677T and A1298C) in Hispanics. Genetic testing. 2003 Sep 1;7(3):255–7. pmid:14642003
- 64. Volcik KA, Blanton SH, Tyerman GH, Jong ST, Rott EJ, Page TZ, Romaine NK, Northrup H. Methylenetetrahydrofolate reductase and spina bifida: evaluation of level of defect and maternal genotypic risk in Hispanics. American Journal of Medical Genetics. 2000 Nov 6;95(1):21–7. pmid:11074490
- 65.
Behrman RE, Butler AS. Prematurity at birth: Determinants, consequences, and geographic variation. InPreterm Birth: Causes, Consequences, and Prevention 2007. National Academies Press (US).
- 66.
Institute of Medicine Staff, Committee to Study the Prevention of Low Birthweight, Institute of Medicine, Division of Health Promotion, Disease Prevention, Division of Health Promotion, Disease Prevention Staff, Study the Prevention of Low Birthweight Committee. Preventing low birthweight. National Academy Press; 1985 Jan 15.
- 67. Wu J, Springett A, Morris JK. Survival of trisomy 18 (Edwards syndrome) and trisomy 13 (Patau Syndrome) in England and Wales: 2004–2011. American Journal of Medical Genetics Part A. 2013 Oct;161(10):2512–8.